Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers

5 years ago
R&D

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

5 years ago
Deals

The cu­ri­ous im­munol­o­gy be­hind the UK's sur­prise As­traZeneca dos­ing plan

5 years ago
R&D

Will they or won't they? The count­down on Bris­tol My­er­s' $6B CVR winds down to a hard dead­line at the FDA

5 years ago
R&D

Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ...

5 years ago
Pharma
FDA+

As­traZeneca/Ox­ford score first vote of con­fi­dence as UK au­tho­rizes their Covid-19 vac­cine

5 years ago
FDA+
Coronavirus

Covid-19 roundup: Mod­er­na of­fers vac­cine to work­ers, con­trac­tors and board mem­bers; Claim­ing 79% vac­cine ef­fi­ca­cy, ...

5 years ago
Coronavirus

EU reg­u­la­tor says As­traZeneca ap­proval not im­mi­nent, even as Pas­cal So­ri­ot teas­es stronger da­ta

5 years ago
Pharma
Coronavirus

FDA lifts clin­i­cal hold on Au­den­tes' gene ther­a­py pro­gram af­ter three pa­tient deaths trig­gered alarms

5 years ago
FDA+

News brief­ing: In­cyte bankrolls an ear­ly-stage myelofi­bro­sis pair-up with Jakafi; In­no­Care gets Chi­nese ap­proval for ...

5 years ago
News Briefing

Af­ter a ‘break­through’ be­gin­ning to 2020, lit­tle Aprea gets crushed by a PhI­II fail­ure

5 years ago
R&D

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

5 years ago
Pharma
FDA+

Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with ...

5 years ago
Deals

What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Here are the top 10

5 years ago
Editor's note

Groups seek clar­i­ty on in­ter­change­abil­i­ty in Bs­U­FA III

5 years ago
FDA+

Covid-19 roundup: Sino­vac pulls back from a promised PhI­II da­ta re­veal, rais­ing ques­tions about ef­fi­ca­cy

5 years ago
Coronavirus

A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White ...

5 years ago
Pharma

Vivek Ra­maswamy's 'van­t' brain­chil­dren keep bear­ing fruit with Urovan­t's FDA nod for in­con­ti­nence med vibegron

5 years ago
FDA+

Al­tim­mune shares slide as the FDA flash­es a red light for the IND work on their in­tranasal Covid-19 vac­cine

5 years ago
FDA+

News brief­ing: Mer­ck buys in­to A2's T cell ther­a­py plat­form; Small Soli­genix re­ports PhI­II fail in head and neck ...

5 years ago
News Briefing

Am­gen hands off rights to lep­rosy, tu­ber­cu­lo­sis med picked up as part of $13.4B Ote­zla deal

5 years ago
Deals
Manufacturing

Cy­to­ki­net­ics may walk a lone­ly road to mar­ket with tar­nished heart med ome­cam­tiv af­ter last part­ner bows out

5 years ago
R&D

Rid­ing on rosy es­ti­mates of Zol­gens­ma sales, Re­genxBio sells part of its roy­al­ty for $200M

5 years ago
Deals
Cell/Gene Tx

Su­per­nus touts win­ning da­ta in adult AD­HD as it looks to make its case with the FDA — again — for pe­di­atric use

5 years ago
R&D
First page Previous page 761762763764765766767 Next page Last page
A service from the Financial Times